ArticleScientific reports2026

DTX3L promotes ovarian cancer progression and cisplatin resistance by activating JAK1/STAT1/OAS3 pathway.

Fangfang Lu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.